Skip to content
akaturk Academic measurement
Search

Article detail · 2013 · article

Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors

YÖKSİS OpenAlex Open access · gold
Year2013
Citations22OpenAlex
Citations23Semantic Scholar
Percentile%86.9
FWCI2.121.00 = world average
Scopus (SJR)Q2
WoS (JCR)Q4

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueAsian Pacific Journal of Cancer Prevention
  • Catalog match (ISSN)Asian Pacific Journal of Cancer Prevention
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

BACKGROUND: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). MATERIALS AND METHODS: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. RESULTS: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (≥30%) was significantly associated with shorter OS (34 vs 95.2 months; 95%CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<%10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that ≥10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. CONCLUSIONS: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

22citationsOpenAlex · cited_by_count (cache / database)

3 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2015 Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?Citations 1 · OpenAlex
  2. 2015 Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?Citations 1 · OpenAlex
  3. 2015 Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?Citations 1 · OpenAlex

Authors

12
  1. LÜTFİYE DEMİR 1
  2. NEŞE EKİNCİ 2
  3. ÇİĞDEM ERTEN 3
  4. YÜKSEL KÜÇÜKZEYBEK 4
  5. AHMET ALACACIOĞLU İZMİR KATİP ÇELEBİ ÜNİVERSİTESİ 5
  6. IŞIL SOMALI 6
  7. ALPER CAN 7
  8. AHMET DİRİCAN 8
  9. İBRAHİM VEDAT BAYOĞLU 9
  10. MURAT AKYOL 10
  11. FULYA ÇAKALAĞAOĞLU 11
  12. MUSTAFA OKTAY TARHAN 12